ASHP therapeutic position statement on the use of statins in the prevention of atherosclerotic vascular disease in adults

American Journal of Health-System Pharmacy

Volumn 60, Issue 6, 2003, Pages 593-598

[No Author Info available]

Author keywords

American Society of Health System Pharmacists; Antilipemic agents; Arteriosclerosis; Mortality; Protocols; Vascular diseases

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; BILE ACID; CHOLESTEROL; CHOLESTEROL ESTER; CLOFIBRATE; COLESTYRAMINE; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; ERYTHROMYCIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVALONIC ACID; MEVINOLIN; NICOTINIC ACID; PHOSPHOLIPID; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DISEASE COURSE; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; ENZYME INHIBITION; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; KIDNEY FAILURE; KINESIOTHERAPY; LIFESTYLE; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; META ANALYSIS; MORTALITY; MYOPATHY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACIST; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; QUALITY ADJUSTED LIFE YEAR; RECEPTOR UPREGULATION; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; STROKE; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; ARTERIOSCLEROSIS; HEALTH CARE ORGANIZATION; HEALTH SERVICES RESEARCH;

ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; HEALTH SERVICES RESEARCH; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; RISK FACTORS; SOCIETIES, PHARMACEUTICAL; UNITED STATES;

EID: 0037445075     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.6.593     Document Type: Article

References (40)

1. American Heart Association. 2002 heart and stroke statistical update. www.americanheart.org/presenter (accessed 2002 May 14).
2. Libby P. The vascular biology of atherosclerosis. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. Philadelphia: Saunders; 2001: 995-1009.
3. Kullo IJ, Edwards WD, Schwartz RS. Vulnerable plaque: pathobiology and clinical implications. Ann Intern Med. 1998; 129: 1050-60.
4. Kwiterovich PO Jr. State-of-the-art update and review: clinical trials of lipid-lowering agents. Am J Cardiol. 1998; 82(12A):3U-17U.
5. Rosenson RS, Tangney CC. Antiathero-thrombotic properties of statins. Implications for cardiovascular event reduction. JAMA. 1998; 279:1643-50.
6. Grundy SM. Consensus statement: role of therapy with "statins" in patients with hypertriglyceridemia. Am J Cardiol. 1998; 81(4A):1B-6B.
7. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994; 16:366-85.
8. Bradford RH, Shear CL, Chremos AN et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Arch Intern Med. 1991; 151:43-9.
9. McEvoy GK, ed. AHFS drug information 2002. Bethesda, MD: American Society of Health-System Pharmacists; 2002.
10. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother. 2001; 35:908-17.
11. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-97.
12. Smith SC, Blair SN, Criqui MH et al. AHA consensus panel statement. Preventing heart attack and death in patients with coronary heart disease. J Am Coll Cardiol. 1995; 26:292-4.
13. Ryan TJ, Anderson JL, Antman EM et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996; 28:1328-428.
14. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-7.
15. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998; 279: 1615-22.
16. Pederson TR, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-9.
17. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-9.
18. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339:1349-57.
19. Kuivenhoven JA, Jukema JW, Zwinderman AH et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary artherosclerosis. N Engl J Med. 1998; 338:86-93.
20. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA. 2001; 285:1711-8.
21. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1998; 128:89-95.
22. Pfeffer MAS, Keech A, Sacks FM et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) project. Circulation. 2002; 105:2341-6.
23. Gaziano JM, Hebert PR, Hennekens CH. Cholesterol reduction: weighing the benefits and risks. Ann Intern Med. 1996; 124:914-8.
24. Heeschen C, Hamm CW, Laufs U et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002; 105:144652.
25. Lewis SJ, Moyé LA, Sacks FM et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol And Recurrent Events (CARE) trial. Ann Intern Med. 1998; 129:681-9.
26. Meittinen TA, Pyörälä K, Olsson AG et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997; 96:4211-8.
27. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360:7-22.
28. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998; 21:160-78.
29. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care. 2003; 26(suppl 1):S83-6.
30. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984; 251:351-64.
31. Clofibrate and niacin in coronary heart disease. JAMA. 1975; 231:360-81.
32. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986; 8:1245-55.
33. Andrade SE, Walker AM, Gottlieb LK et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995; 332:1125-31.
34. Hay JW, Yu WM, Ashraf T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics. 1999; 15:47-74.
35. Hay JW. Economic modeling and sensitivity analysis. Value Health. 1998; 1:187-93.
36. Shibley MC, Pugh CB. Implementation of pharmaceutical care services for patients with hyperlipidemias by independent community pharmacy practitioners. Ann Pharmacother. 1997; 31:713-9.
37. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT: hyperlipidemia. J Am Pharm Assoc. 2000; 40:157-65.
38. Tullio CJ, Goode DL. Identifying ambulatory care patients with coronary heart disease who need cholesterol management. Am J Health-Syst Pharm. 1998; 55:1769-71.
39. Interim Report from Project Impact: Hyperlipidemia. Collaborative practice model shows promise for improving patient care. J Am Pharm Assoc. 1998; 38:529-34.
40. Furmaga EM. Pharmacist management of a hyperlipidemia clinic. Am J Hosp Pharm. 1993; 50:91-5.